What is Leerink Partnrs’ Forecast for Climb Bio Q2 Earnings?

Climb Bio, Inc. (NASDAQ:CLYM) – Analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of Climb Bio in a research note issued on Tuesday, March 25th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.15) for the quarter, up from their previous estimate of ($0.16). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio’s FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($1.10) EPS, FY2028 earnings at ($1.73) EPS and FY2029 earnings at ($2.69) EPS.

Separately, Leerink Partners started coverage on shares of Climb Bio in a research note on Monday, December 2nd. They issued an “outperform” rating and a $10.00 price objective for the company.

Climb Bio Price Performance

Shares of NASDAQ:CLYM opened at $1.27 on Friday. The firm has a market cap of $85.37 million, a P/E ratio of -0.60 and a beta of -0.19. Climb Bio has a 1 year low of $1.20 and a 1 year high of $11.55. The company has a 50-day simple moving average of $1.56.

Climb Bio (NASDAQ:CLYM) last released its earnings results on Tuesday, March 25th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.